Home › Moberg Pharma announces successful results for MOB-015 in a Phase II...
 

Keywords :   


Moberg Pharma announces successful results for MOB-015 in a Phase II...

2014-09-17 10:42:21| Appliances - Topix.net

Moberg Pharma AB announces successful top-line results from a phase II study for MOB-015 in onychomycosis . The primary endpoint, mycological cure after 15 months, was achieved in 54% of the patients.

Tags: results ii successful phase

Category:Consumer Goods and Services

Latest from this category

All news
03.07How Microsoft and Nvidia bet correctly to leapfrog Apple
02.07Tesla sales rise sharply after slump
02.07Almost 1.8m people owe 50,000 or more in student debt
02.07Levelling up: Can the next government help the UK games industry?
02.07Levelling up: Can the next government help the UK games industry?
02.07Cheap TVs ahead of Euros help slow price inflation
02.07Murdoch Netflix rival to launch in UK
02.07The fastest data in the world
Consumer Goods and Services »
03.07Hurricane Beryl Graphics
03.07Hurricane Beryl Forecast Discussion Number 19
03.07Hurricane Beryl Wind Speed Probabilities Number 19
03.07Hurricane Beryl Public Advisory Number 19
03.07Summary for Hurricane Beryl (AT2/AL022024)
03.07Hurricane Beryl Forecast Advisory Number 19
03.07Hurricane Beryl Graphics
03.07Hurricane Beryl Public Advisory Number 18A
More »